3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Figure Technology Solutions reported unaudited, preliminary operating data for September and the third quarter of 2026. Consumer Loan Marketplace Volume was $5.1 billion for the quarter, at the high end of its $4.8 billion to $5.2 billion guidance range. The figures exclude Kiavi volume after the merger closed on September 1, 2026, which will be included in third-quarter financial results due in November.
Q3 2026 Consumer Loan Marketplace Volume of $5,119 million, up 20% from Q2 2026 and up 107% from Q3 2025 ($2,469 million)
September 2026 Consumer Loan Marketplace Volume of $1,783 million, up 9% from August 2026
$YLDS in Circulation of $504 million at September 2026 end, down 9% from Q2 2026 but up from $21 million a year earlier
Kiavi loan volume for roughly one month after the September 1, 2026 merger closing will be included in Q3 2026 results, to be released in November
Penguin Solutions reported fourth-quarter fiscal 2026 net sales of $567 million, up 68% year over year, and GAAP diluted EPS of $1.29 versus $0.11 a year earlier. The company raised its fiscal 2027 outlook, now expecting net sales of about $2.43 billion at the midpoint, growth of about 40%, which it attributes to AI Infrastructure demand.
Q4 fiscal 2026: net sales $567 million, up 68%; GAAP diluted EPS $1.29 vs. $0.11; non-GAAP diluted EPS $1.00 vs. $0.43
Full fiscal 2026: net sales $1.73 billion, up 26%; net income attributable to Penguin Solutions $181 million
Fiscal 2027 outlook: net sales about $2.43 billion at midpoint (about 40% growth); GAAP diluted EPS $3.50; non-GAAP diluted EPS $4.45
The sponsor, 21Shares US LLC, agreed on October 6, 2026 to extend its voluntary waiver of the sponsor fee for the 21Shares Ethereum Staking ETF (TETH) for one more year, through October 8, 2027. The filing says the waiver extension applies automatically to current and prospective shareholders, and the press release cites a net staking reward of 2.65% as of October 1, 2026.
Sponsor fee waiver extended 12 months, through October 8, 2027
The 100% waiver was first introduced alongside staking features in October 2025
Net staking reward for TETH was 2.65% as of October 1, 2026, per the press release, which says this is not a projection and not reflective of overall Trust performance
Constellation Brands reported fiscal second-quarter 2027 net sales up 6% to $2,633 million and reported EPS up 25% to $3.32, though reported operating income fell 8% to $805 million. The company raised its fiscal 2027 reported EPS outlook to $11.85-$12.55 and reaffirmed its comparable EPS outlook of $11.20-$11.90, and it also announced the completed SpikedAde acquisition and a $1.03 quarterly dividend.
Net sales rose 6% to $2,633 million; reported operating income fell 8% to $805 million, and reported operating margin was 30.6% versus 35.2% a year earlier.
Reported EPS was $3.32, up 25%; comparable EPS was $3.74, up 3%.
Fiscal 2027 reported EPS outlook updated to $11.85-$12.55; comparable EPS outlook reaffirmed at $11.20-$11.90.
Quarterly dividend of $1.03 per Class A share is payable November 13, 2026, to holders of record on October 30, 2026; SpikedAde acquisition included a $75 million payment at close and up to $278 million of contingent consideration over five
Bridgeline Digital reported sales results for the fiscal fourth quarter and year ended September 30, 2026, citing record new customer acquisitions led by its HawkSearch platform. The filing gives sales-bookings metrics but no total revenue, net income or EPS figures, and it reaffirms expectations of double-digit growth for Core products in fiscal 2026.
Fourth quarter: 12 new customers, a record, with $1.4 million in TCV and over $400,000 in ARR
Fiscal 2026: 38 new customers with $3.9 million in TCV and $1.2 million in ARR, a record year for new customer acquisition
Company expects Core products to be 61% of total fiscal 2026 revenue and to achieve double-digit growth and NRR above 105%
Company ended fiscal 2026 with approximately $1.0 million in cash and less than $200,000 in legacy bank debt
Gulf Resources received a letter from Nasdaq's Listing Qualifications staff on October 1, 2026, stating it had regained compliance with the periodic filing requirement under Listing Rule 5250(c)(1) and that the staff determined it complies with the rule. The company announced the development in a press release dated October 6, 2026. For shareholders, this means the company's Nasdaq listing is no longer subject to this filing deficiency.
Nasdaq staff letter dated October 1, 2026 confirms compliance with Listing Rule 5250(c)(1)
Press release issued October 6, 2026 and filed as Exhibit 99.1
Company remains listed on The Nasdaq Capital Market per the press release
Blue Bird Corporation entered into a Second Amendment to its Credit Agreement, raising total committed facilities to $600 million from $250 million and extending maturity to September 30, 2031. Pricing falls to SOFR plus 1.25% to 2.25%, based on leverage, from SOFR plus 1.75% to 3.25%, and the new delayed draw term loan can fund capital projects, research and development, working capital, or refinance existing debt. The maximum total net leverage ratio rises to 3.25x, and the company also closed a separate Canadian dollar line for its Micro Bird unit.
Total facilities rise to $600 million from $250 million, including a $300 million revolver (up from $150 million) and a $300 million delayed draw term loan
Maturity extended from November 17, 2028 to September 30, 2031
Margin lowered to SOFR plus 1.25% to 2.25% from SOFR plus 1.75% to 3.25%; 0.10% credit spread adjustment eliminated
At closing, about $86 million was carried over as drawn debt, with $214 million available to draw under the Borrower's facilities and $670+ million of liquidity per the press release
Worksport said preliminary August 2026 sales orders were about $2.92 million, up 16.4% from July, and preliminary net sales rose 5.6% to $2.34 million. Estimated backlog grew 145.1% to about $898,000 because orders exceeded invoicing, and the company reported gross margin above 30% for a fourth consecutive month. The monthly figures are preliminary and unaudited, and the filing states that the run-rate metrics are not forecasts or full-year guidance.
August sales orders of about $2.92 million, up 16.4% from about $2.51 million in July
Preliminary August net sales of $2.34 million, up 5.6%; invoiced sales about $2.39 million
Estimated month-end backlog of about $898,000, up 145.1% from an updated July balance of about $366,000
Annualized sales-order run rate of about $35.05 million; the company said August was the fourth consecutive month with preliminary gross margin above 30%
Safe Harbor said preliminary, unaudited trailing 14-day average client deposits were $119.3 million as of September 30, 2026, up 7.4% from $111.1 million a year earlier and the highest quarter-end level since April 2024. The company stresses these deposits belong to clients, are held at partner banks, and are not its revenue or balance-sheet assets, and it will report full third quarter results at a later date.
Trailing 14-day average client deposits were approximately $119.3 million at September 30, 2026, versus $111.1 million at September 30, 2025.
Deposits rose about 9.6% sequentially from $108.9 million at June 30, 2026, after a 4.1% increase in the second quarter.
The company estimates the September 16, 2026 Federal Reserve 25-basis-point rate increase will add about $150,000 in annualized investment income, based on current balances and arrangements.
Figures are preliminary and unaudited; full third quarter 2026 financial results will be reported at a later date to be announced.
Option Care Health entered into a merger agreement on October 5, 2026, under which an investor group of CD&R affiliates and McKesson Corporation would acquire the company for $32.05 per share in cash, a total enterprise value of approximately $5.8 billion. The price represents a premium of approximately 37% to the October 5, 2026 closing share price, and the company's board unanimously recommended the deal to stockholders. Shareholders would receive cash and the stock would no longer be publicly listed on Nasdaq once the deal closes, which is expected in the first half of 2027, subject to stockholder and regulatory approvals.
Cash consideration of $32.05 per share, a premium of approximately 37% to the October 5, 2026 closing price
Total enterprise value of approximately $5.8 billion; McKesson to invest approximately $1.4 billion for an approximately 49% minority interest
Closing expected in the first half of calendar year 2027, subject to stockholder approval and regulatory approvals
Company is withdrawing its previously disclosed 2026 guidance and will not host a call for its third quarter 2026 results, which it expects to release on November 4, 2026
Regeneron and Sanofi amended their antibody collaboration on October 1, 2026, to co-develop and co-commercialize four new long-acting antibodies. Sanofi will pay Regeneron a $1.0 billion upfront payment, with up to $7.0 billion more in milestones, and the two companies will share global profits equally. Regeneron also expects a third-quarter 2026 acquired IPR&D charge of about $22 million, or $0.18 per diluted share, and agreed to dismiss a lawsuit against Sanofi.
Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment dated October 1, 2026.
Regeneron is eligible for up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
Regeneron expects a third-quarter 2026 acquired IPR&D charge of about $22 million pre-tax, reducing GAAP and non-GAAP EPS by about $0.18 per diluted share.
Regeneron agreed to dismiss its lawsuit over Sanofi's obligations to provide information on Dupixent commercialization and audit rights.
Kairos Pharma said interim Phase 2 data showed a statistically significant difference in progression-free survival for patients treated with ENV-105 plus apalutamide compared with apalutamide alone. The company also modified the trial protocol to enroll patients earlier in disease progression, with completion targeted in or before the fourth quarter of 2027.
Median progression-free survival was 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone (P=0.0008).
The modified protocol enrolls patients after a PSA increase following upfront androgen signaling inhibitor treatment, randomized to enzalutamide alone or with ENV-105.
Kairos Pharma targets completing the Phase 2 trial in or before the fourth quarter of 2027.
Beeline Holdings said preliminary third-quarter 2026 results show revenue at its second-highest quarterly level in company history and its highest since 2021, along with its highest margins ever. The company also expects a smaller net loss and a smaller adjusted EBITDA loss than in the prior quarter, plus a cash position at least 50% above the end of Q2 2026, and announced a pending Home Equity Investment product. The figures are preliminary and remain subject to quarter-end close and auditor review.
Q3 2026 revenue expected to be the second-highest quarterly revenue in company history and the highest since 2021
Q3 2026 net loss expected to be lower than the Q2 2026 net loss; adjusted EBITDA loss expected to be the lowest in 5 years
Cash at end of Q3 2026 expected to be at least 50% higher than at end of Q2 2026
Pending Home Equity Investment (HEI) product launch, which the company says is less tied to interest rates
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.